Effect of tailored Helicobacter pylori eradication with platelet count recovery in immune thrombocytopenic purpura

Seoul National University Hospital0 个研究点目标入组 30 人开始时间: 待定最近更新: 2020年2月24日

适应症

试验速览

暂无简介。

•1. Men and women over 18 years of age at the time of initial diagnosis
•2. At least one positive serum anti-helicobacter antibody or urease breath test
•3. Patients with platelet count 40 × 10^3 / µL or more at initial diagnosis
•4. Able to read, understand and voluntarily provide written Informed Consent.

•1. Age under 18 at diagnosis
•2. Patients with platelet count less than 40 × 10^3 / µL at first diagnosis
•3. Subjects who have previously been treated with Helicobacter pylori eradication
•4. Other causes of thrombocytopenia include: autoimmune diseases, hepatitis C virus infection, liver disease, HIV infection, pseudothrombocytopenia
•5. Patients taking an immunosuppressant for other disease(s)
•6. Patients treated with other solid tumors when idiopathic thrombocytopenia is diagnosed
•7. In the case of severe medical or surgical conditions that cannot be followed up in the future
•8. Have taken proton pump inhibitors, H2RA, potassium competitive acid blocker (P-CAB), bismuth agents, non-steroidal anti-inflammatory drugs, or antibiotics within the last 4 weeks
•9. Patients with history of penicillin allergies or anaphylaxis
•10. If the researcher judges that participation in this study is inappropriate

发起方